

Dated: October 30, 1997.

Joanne Lanahan,

Director, Health Care Administrative Sanctions, Office of Investigations, OI.
[FR Doc. 97-29792 Filed 11-12-97; 8:45 am]
BILLING CODE 4150-04-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment Request; 'Test-Retest Study of the Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS-IV) in a General Population Sample'

SUMMARY: In compliance with Section 3506(c)(2)(A) of the Paperwork

Reduction Act of 1995, which provides for an opportunity for public comment on proposed data collection projects, the National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Proposed Collection

The Biometry Branch (BB), Division of Biometry and Epidemiology (DBE), NIAAA, intends to conduct the 'Test-Retest Study of the Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS-IV) in a General Population Sample' to assess the test-retest reliability of new sections of the AUDADIS-IV in a general population sample. The AUDADIS-IV is

a fully-structured interview designed to collect information on alcohol and drug use disorders and their associated psychiatric and medical conditions. The NIAAA is authorized by Section 464H of Title IV of the Public Health Act (42 U.S.C. 285n).

The information proposed for collection in this study will be used by the NIAAA to develop and finalize psychometrically sound measures of alcohol and drug-related disabilities for use in major epidemiologic surveys conducted in the United States. Currently, there is a great need for more reliable measurement of alcohol and drug use disorders and their associated disabilities in all fields of substance use research.

The annual burden estimates are as follows:

Type and number of respondents	Responses per respondent	Total responses	Hours	Total hours
(First (Test Interviews) 500	1	500	1	500
(Second (Retest) Interviews) 500	1	500	1	500
Total Number of Respondents—500 (per year)				
Total Number of Responses—1000 (per year)				
Total hours—1000 (per year)				

Request for Comments

Comments are invited on: (a) Whether the proposed collection is necessary, including whether the information has practical use; (b) ways to enhance the clarity, quality, and use of the information to be collected; (c) the accuracy of the agency estimate of burden of the proposed collection; and (d) ways to minimize the collection burden of the respondents. Send written comments to Dr. Bridget Grant, Biometry Branch, Division of Biometry and Epidemiology (DBE), NIAAA, NIH, Willco Bldg., Suite 514, 6000 Executive Boulevard, Bethesda, Maryland 20892-7003.

For Further Information

To request more information on the proposed project or to obtain a copy of the data collection plans, contact Dr. Bridget Grant, Biometry Branch, Division of Biometry and Epidemiology, NIAAA, Willco Bldg., 6000 Executive Boulevard, Suite 514, Bethesda, Maryland 20892-7003, or call non-toll-free number (301) 443-7370.

Comments Due Date

Comments regarding this information collection are best assured of having their full effect if received on or before January 12, 1998.

Dated: November 5, 1997.

Martin K. Trusty,

Executive Officer, NIAAA.
[FR Doc. 97-29841 Filed 11-12-97; 8:45 am]
BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National

Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Identification of the Gene Causing Familial Mediterranean Fever

D Kastner (NIAMS) et al.
Serial No. 60/056,217 filed 21 Aug. 97
Licensing Contact: Stephen Finley, 301/496-7056 ext. 215

The invention identifies the gene (MEFV) encoding the protein (pyrin) that is associated with familial Mediterranean fever (FMF). FMF, a recessive inherited disorder, is characterized by episodes of fever, inflammation, and unexplained arthritis, pleurisy, or abdominal pain. Pypin is thought to play a role in keeping inflammation under control, whereas mutated forms lead to a malfunctioning protein and uncontrolled inflammation. Mutated forms of MEFV were isolated and correlated to FMF disease. It is anticipated that the immediate use of the pyrin gene and its mutations will be to aid in the diagnosis of FMF. It may also prove useful for evaluating FMF as a possible cause of currently unexplained fevers or abdominal pain.